After high-dose treatment, the relative percentage of CD3+ T cells among CD45+ leukocytes increased by 2.1–7.8 fold, and the cell numbers per milligram of tumor tissue increased by 2.6–26.0 fold (Figure 2B and Supplementary Figure S2). Here, PTPRC is linked to neoplasm.